Advertisement

Digestive Diseases and Sciences

, Volume 34, Supplement 12, pp S24–S35 | Cite as

Structure-activity relationship studies on natural and synthetic bile acid analogs

  • Aldo Roda
  • Brunella Grigolo
  • Roberto Pellicciari
  • Benedetto Natalini
Advances in Bile Acid Therapy

Abstract

The objective of our research was to develop ursodiol analogs that are structurally modified to modulate hepatic side-chain amidation and prevent 7-dehydroxylation by intestinal bacteria while at the same time maintaining the critical micellar concentration (CMC) and hydrophilicity of ursodiol. More than 20 naturally occurring bile acids were screened for physicochemical properties. Then, two generations of analogs were studied, and those with physicochemical properties similar to ursodiol's were analyzed for physiologic properties. The first generation of analogs included molecules with steric and/or electronic hindrance on the side chain; the second group consisted of the same molecules conjugated with glycine or taurine and also “pseudoconjugated” analogs (23-hydroxylated, esterified, and amidated with other amino acids). Of the first-generation analogs, only cyclopropane D derivative and trans-olefin were useful to our purposes, being conjugated by the liver and almost completely recovered in bile. These two analogs were deconjugated and 7-dehydroxylated but with slower kinetics. The hydrophilicity of the molecules could be augmented by increasing the polarity of the steroid ring. Among the pseudoconjugated analogs, the CMC values were similar to those of the natural analogs, although hydrophobicity differed among the group. The analogs that were not deconjugated were not 7-dehydroxylated either. All of the pseudoconjugated bile acids were efficiently taken up by the liver, and their recovery in bile was similar to that of glycine and taurine ursodiol. From these studies we now know that side chain configuration and conformation are important in the conjugation and deconjugation processes. Mild modification of the side chain can prevent 7-dehydroxylation and thus yield a bile acid more resistant to intestinal bacteria and more bioavailable. Prevention of hepatic conjugation improves biliary secretion and recovery of many analogs.

Key words

bile acids bile acid structure-activity relationship bile acid analogs cholesterol gallstones 

References

  1. 1.
    Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL: Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 268:1–8, 1972Google Scholar
  2. 2.
    Schoenfield LJ, Lachin JM, The Steering Committee: Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med 95:257–282, 1981PubMedGoogle Scholar
  3. 3.
    Nakagawa S, Makino I, Ishizaki T, Dohi I: Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 2:367–369, 1977PubMedGoogle Scholar
  4. 4.
    Roda E, Bazzoli F, Morselli Labate AM, Mazzella G, Roda A, Sama C, Festi D, Aldini R, Barbara L: Ursodeoxycholic acid vs chenodeoxycholic acid as cholesterol gallstone-dissolving agents: A comparative randomized study. Hepatology 2:804–810, 1982PubMedGoogle Scholar
  5. 5.
    Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig Dis Sci 27:737–856, 1982PubMedGoogle Scholar
  6. 6.
    Frigerio G: Ursodeoxycholic acid (UDCA) in the treatment of dyspepsia: Report of a multicenter controlled trial. Curr Ther Res 26:214–224, 1979Google Scholar
  7. 7.
    Stefaniwsky AB, Tint GS, Speck J, Shefer S, Salen G: Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology 89:1000–1004, 1985PubMedGoogle Scholar
  8. 8.
    Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosiniani A, Petroni ML, Zuin M: Ursodeoxycholic acid for chronic liver disease. J Clin Gastroenterol 10(Suppl 2):S25-S31, 1988PubMedGoogle Scholar
  9. 9.
    Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K: Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow up. A pilot study. Dig Dis Sci 30:642–649, 1985PubMedGoogle Scholar
  10. 10.
    David R, Kurtz W, Strohm WD, Leuschner U. Die wirkung von ursodesoxycholsaure bei chronischnen leberkrankungen: Eine pilot Studie. Z Gastroenterol 23:420, 1985 (abstract)Google Scholar
  11. 11.
    Fisher MM, Paradine ME: Influence of ursodeoxycholic acid on biochemical parameters in cholestatic liver disease. Gastroenterology 90:1725, 1986; (abstract)Google Scholar
  12. 12.
    Poupon R, Chretien Y, Pupon RE, Pallet F, Calmus Y, Darms F: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1:834–836, 1987PubMedGoogle Scholar
  13. 13.
    Ghezzi C, Zuin M, Battezzati PM, Podda M: Effect of ursodeoxycholate taurine and ursodeoxycholate plus taurine on serum enzyme levels in patients with chronic hepatitis. Hepatology 7:1110, 1987 (abstract)Google Scholar
  14. 14.
    Carey MC, Small DM: The physical chemistry of cholesterol solubility in bile: Relationship to gallstone formation and dissolution in man. J Clin Invest 61:998–1026, 1978PubMedGoogle Scholar
  15. 15.
    Holzbach RT, Marsh M, Olszewski M, Holan K: Cholesterol solubility in bile: Evidence that supersaturated bile is frequent in healthy man. J Clin Invest 52:1467–1479, 1973PubMedGoogle Scholar
  16. 16.
    Roda E, Mazella G, Roda A, Aldini R, Festi D, Bazzoli F, Messale E, Morselli AM, Barbara L: Effect of chenodeoxycholic and ursodeoxycholic acid administration on biliary lipid secretion in normal weight and obese gallstone patients.In Bile Acids and Lipids. G Paumgartner, A Stiehl, W Gerok, (eds). Lancaster, England: MTP Press, 1980Google Scholar
  17. 17.
    Loria P, Carulli N, Medici G, Menozzi D, Salvioli G, Bertolotti M, Montanari M: Effect of ursocholic acid on bile lipid secretion and composition. Gastroenterology 90:865–874, 1986PubMedGoogle Scholar
  18. 18.
    Northfield TC, Hofmann AF: Biliary lipid output during three meals and an overnight fast: I. Relationship to bile acid pool and cholesterol saturation of bile in gallstone and control subjects. Gut 16:1–11, 1975PubMedGoogle Scholar
  19. 19.
    Mosbach EH: Approaches to the development of new cholelitholytic agents.In Bile Acids and Cholesterol in Health and Disease. G Paumgartner, A Steihl, W Gerok, (eds). Lancaster, England, MTP Presss, 1983, pp 11–20Google Scholar
  20. 20.
    Mizuho U, Bertram IC, Mosbach EH: New bile acid analogs: 3α,7α-dihydroxy-7β-methyl-5β-cholanoic acid, 3α,7β-dihydroxy-7α-methyl-5β-cholanoic acid, and 3α-hydroxy-7-methyl-5β-cholanoic acid. J Lipid Res 25:407–410, 1984PubMedGoogle Scholar
  21. 21.
    Pellicciari R, Cecchetti S, Natalini B, Roda A, Grigolo B, Fini A: Bile acids with a cyclopropyl containing side chain. 1. Preparation and properties of 3α,7β-dihydroxy-22,23-methylene-5β-cholan-24-oic acid. J Med Chem 27:746–749, 1984PubMedGoogle Scholar
  22. 22.
    Pellicciari R, Cecchetti S, Natalini B, Roda A, Grigolo B, Fini A: Bile acid with cyclopropane containing side chain. 2. Synthesis and properties of 3α, 7β-dihydroxy-22,23-methylene-5β-cholan-24-oic acid-N-(2-sulfo-ethyl)amide. J Med Chem 28:239–242, 1985PubMedGoogle Scholar
  23. 23.
    Roda A, Grigolo B, Aldini R, Simoni P, Pellicciari R, Natalini B, Balducci R: Bile acids with a cyclopropyl-containing side chain. IV. Physicochemical and biological properties of the four diasteroisomers of 3α,7β-dihydroxy-22,23-methylene-5β-cholan-24-oic acid. J Lipid Res 28:1384–1397, 1987PubMedGoogle Scholar
  24. 24.
    Roda A, Aldini R, Grigolo B, Simoni P, Roda E, Pellicciari R, Lenzi PL, Natalini B: 23-Methyl-3α,7β-dihydroxy-5β-cholan-24-oic acid. Dose-response study of biliary secretion in rat. Hepatology 8:1571–1576, 1988PubMedGoogle Scholar
  25. 25.
    Roda A, Hofmann AF, Mysels KJ: The influence of bile salt structure on self-association in aqueous solution. J Biol Chem 258:6362–6370, 1983PubMedGoogle Scholar
  26. 26.
    Hofmann AF, Roda A: Physicochemical properties of bile acid and their relationship to biological properties: an overview of the problem. J Lipid Res 25:1477–1489, 1984PubMedGoogle Scholar
  27. 27.
    Roda A, Fini A: Effect of nuclear hydroxy substituents on aqueous solubility and acidic strength of bile acids. Hepatology 4(Suppl):72S-76S, 1984Google Scholar
  28. 28.
    Zouboulis Vafiadis I, Dumont M, Erlinger S: Conjugation is rate limiting in hepatic transport of ursodeoxycholate in the rat. Am J Physiol 243:G208-G213, 1982PubMedGoogle Scholar
  29. 29.
    Fedorowsky T, Salen G, Colallilo A, Tint GS, Mosbach EH, Hall JC: Metabolism of ursodeoxycholic acid in man. Gastroenterology 73:1131–1137, 1977PubMedGoogle Scholar
  30. 30.
    Fisher CD, Cooper NS, Rothschild MA, Mosbach EH: Effect of dietary chenodeoxycholic acid and lithocholic acid in the rabbit. Am J Dig Dis 19:877–886, 1974PubMedGoogle Scholar
  31. 31.
    Roda A, Fini A, Grigolo B, Simoni P, Rusticali GA, Natalini B: Factor analysis of physico-chemical properties of bile acids. Ann Chim 78:15–23, 1988Google Scholar
  32. 32.
    Fini A, Roda A, De Maria P: Chemical properties of bile acids. Part 2. pKa values in water and aqueous methanol of some hydroxy bile acids. Eur J Med Chem 17:467–470, 1982Google Scholar
  33. 33.
    Fini A, Roda A, Fugazza R, Grigolo B: Chemical properties of bile acids. III. Acid structure and solubility in water. J Solution Chem 14:595–603, 1985Google Scholar
  34. 34.
    Aldini R, Roda A, Morselli Labate AM, Cappelleri G, Roda E, Barbara L: Hepatic bile acid uptake: Effect of conjugation, hydroxyl and keto groups, and albumin binding. J Lipid Res 23:1167–1173, 1982PubMedGoogle Scholar
  35. 35.
    Aldini R, Roda A, Morselli AM, Simoni P, Roda E, Barbara L: Effect of albumin on taurocholate uptake kinetics in rat liver. Clin Sci 72:11–17, 1987PubMedGoogle Scholar
  36. 36.
    Aldini R, Roda A, Morselli AM, Grigolo B, Simoni P, Roda E, Barbara L: Species differences of the hepatic uptake of bile acids. Ital J Gastroeterol 19:1–4, 1986Google Scholar
  37. 37.
    Roda A, Grigolo B, Roda E, Simoni P, Pellicciari R, Natalini B, Fini A, Morselli Labate AM: Quantitative relationship between bile acid structure and biliary lipid secretion in rats. J Pharm Sci 77:596–605, 1988PubMedGoogle Scholar
  38. 38.
    Pellicciari R, Natalini B, Cecchetti S, Porter B, Roda A, Grigolo B, Balducci R: Bile acids with a cyclopropyl-containing side chain. 3. Separation, identification and properties of all four stereoisomers of 3α, 7β-dihydroxy-22,23-methylene-5β-cholan-24-oic acid (CUDCA). J Med Chem 31:730–736, 1988PubMedGoogle Scholar
  39. 39.
    Pellicciari R, Natalini B, Marinozzi M, Ursini A, Roda A, Grigolo B: Reazioni di ossidazione di alchilsililcheteneacetali e loro applicazioni nella sintesi di acidi biliari naturali 23-ossidrilati. Atti del VI Congresso Nazionale della Divisione di Chimica Farmaceutica della SCI, Alghero, 1986Google Scholar
  40. 40.
    Armstrong MJ, Carey MC: The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol solubilizing capacities. J Lipid Res 23:70–80, 1982PubMedGoogle Scholar
  41. 41.
    Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH: Effect of side-chain shortening on the physiologic properties of bile acids: Hepatic transport and effect on biliary secretion of 24-nor-ursodeoxycholate in rodents. Gastroenterology 90:837–852, 1986PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • Aldo Roda
    • 1
    • 2
    • 3
  • Brunella Grigolo
    • 1
    • 2
    • 3
  • Roberto Pellicciari
    • 1
    • 2
    • 3
  • Benedetto Natalini
    • 1
    • 2
    • 3
  1. 1.Istituto di Chimica AnaliticaUniversitá di MessinaItaly
  2. 2.Cattedra di GastroenterologiaUniversitá di BolognaItaly
  3. 3.Instituto di Chimica FarmaceuticaUniversitá de PerugiaItaly

Personalised recommendations